SK Biopharmaceuticals

Sustainability

A global pioneer in the development of new drugs

2030 Sustainability Strategy

SK Biopharmaceuticals is contributing to a healthier future for patients and society by creating balanced economic and social value. SK Biopharmaceuticals’ 2030 Sustainability Strategy is built around three pillars: Value in SKBP, Value with Partners, and Value to Society.
By linking key targets in each strategic area to company-wide KPIs, SK Biopharmaceuticals enhances execution and, through transparent communication with stakeholders, is advancing toward ‘Evolving into a Global Top-tier and Sustainable Pharmaceutical Company’.

Evolving into a Global Top-tier and Sustainable Pharmaceutical Company with a Balanced Growth in Economic and Social Values

2030 Strategic Goals

In progress

Achieved

2030 Strategic Goals
Core Objectives	Focus Areas	Goals	Achieving Status	2025-2026 Highlights
Value in SKBP	Innovation	Initiate clinical trials for a new technology pipeline using next-generation R&D platforms by 2030	In progress	Initiated global phase 1 IND for SKL35501 and in-licensed second candidate Continued review and market screening of second product/pipeline in-licensing targets
	Innovation	Acquire a 2nd Product	In progress
	Transparent and Ethical Management	Strengthen Board composition by prioritizing independence, expertise, and diversity	Achieved	Female directors on the Board: 43%(3 appointed) 100% of ethics reports resolved
	Transparent and Ethical Management	Advance the audit framework and ensure full implementation	Achieved
	Employee Competency and Satisfaction	Continue to expand and develop talent-building programs	Achieved	Conducted training by job level and leadership training Introduced AI Literacy training Conducted the Culture Pulse Survey, with the happiness score improving by 4 points year-over-year
	Employee Competency and Satisfaction	Strengthen efforts to assess and enhance employee well-being	Achieved
Value with Partners	Product Quality and Safety	Continue to strengthen quality management systems to prevent product issues and ensure zero regulatory violation worldwide	Achieved	Maintained zero product quality incidents and zero recalls Established and implemented a Quality Management System(QMS) process improvement plan
Value with Partners	Sustainable Partnerships	Maintain 100% audit coverage of core suppliers and strengthen overall compliance across the supply chain	Achieved	Revised the Global Supplier Code of Conduct Maintained 100% audit coverage of core suppliers Monitored corrective action implementation across all audits
Value to Society	Creating Healthcare Value	At least double the company’s social value created by 2030 compared to 2023	In progress	2025 Social Value measurement results in the social dimension increased by approximately 47% compared to 2023
Value to Society	Strengthening Environmental Responsibility	Achieve net-zero greenhouse gas emissions by 2040	In progress	Reduced greenhouse gas emissions by 16% compared to the 2020 Business-as-Usual (BAU) baseline